Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
Toucan Health Innovations from Etterbeek, company number BE0674398735, closed financial year 2025 with a result of € -13,104 after tax. For that financial year Toucan Health Innovations recorded a gross margin of € -15,602 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € 16,150 to € -13,104. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 25, 2026.
€ 1.6 million
▼ 1% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -13,104
▼ still € 16,150 profit in 2024
Profit after tax over the fiscal year.
€ 137,831
▼ 75% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 221,968.
Debts at end 2025
€ 65,000
Loans from banks and other lenders, long and short.
€ 5,987
▲ 33% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 106,876 | € 65,328 | € 23,328 | € -15,602 | ▼ € 38,930 |
| Profit after taxes | € 78,885 | € 48,244 | € 16,150 | € -13,104 | ▼ € 29,254 |
| Equity | € 201,477 | € 249,721 | € 1,614,871 | € 1,601,768 | ▼ 1% |
| Total debts | € 126,012 | € 262,356 | € 120,106 | € 123,342 | ▲ 3% |
| Cash | € 28,896 | € 96,960 | € 558,534 | € 137,831 | ▼ 75% |
| Retained profit | € 173,477 | € 218,921 | € 235,071 | € 221,968 | ▼ 6% |
| Bank debt | € 50,000 | € 200,000 | € 65,000 | € 65,000 | |
| Balance sheet total | € 327,489 | € 512,077 | € 1,734,978 | € 1,725,110 | ▼ 1% |
Key figures of Toucan Health Innovations, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Toucan Health Innovations?
What happened at Toucan Health Innovations in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 13,104 (▼ € 29,254 vs 2024). filed late Source: NBB ↗
- New establishment in Etterbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 78,885 profit in 2022 to € 13,104 loss in 2025.
Paid € 48,618 in corporate taxes since 2022.
Best year ever: 2022, with € 78,885 profit.
A new publication or filing at Toucan Health Innovations? We notify you, reason included.
Follow Toucan Health InnovationsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Toucan Health Innovations are Marcio Scorsin and Tatyana Andreeva . It owns 100% of S-FORM PHARMA, 24.9% of Precisia Care , 20% of MYTHRALICA, 3.7% of 4TEEN4 Pharmaceuticals and 2.1% of PAM Theragnostics itself.
Directors
According to the 2025 annual accounts
Marcio Scorsin
Director
Tatyana Andreeva
Director
Also active at: ABI PLACE, GEDECE, COFISAF HOLDING, ENMORE, MONOCOM, Mali Investment, Sante Angelo Equity Limited, EUFUNDING CONSULT +5 more
Establishments
Establishment units
Physical locations of this company
Priester Cuypersstraat 3
1040 Etterbeek
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0674.398.735
- VAT number
- BE 0674.398.735
- Registered office
- Priester Cuypersstraat 3, 1040 Etterbeek
- Names & denominations
- Toucan Health Innovations
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 April 2017
- Peppol
- Not registered
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering